Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

Patent
Alnylam Pharmaceuticals | Date: 2016-07-18

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.


Patent
Alnylam Pharmaceuticals | Date: 2015-04-23

Assays, methods, reagents and kits for evaluating the level of an antibody against a nucleic acid molecule, e.g., a double-stranded oligonucleotide or RNA molecule (e.g., dsRNA), are disclosed herein.


Patent
Alnylam Pharmaceuticals | Date: 2016-10-28

The present invention relates to assays and methods for the detection of transthyretin and its isoforms. Specifically, the assays and methods of the present invention embrace liquid chromatography and mass spectrometry. The present invention also relates to unique peptides and peptide variants useful in the assays and methods.


Patent
Alnylam Pharmaceuticals | Date: 2015-01-09

One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene in vivo. The dsRNA duplex comprises one or more 4-modifications in one or both strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for in vivo therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.


The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.


Patent
Alnylam Pharmaceuticals | Date: 2017-03-15

The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R^(N)) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, - P(Z)(Z)0- nucleoside, -P(Z)(Z)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, P(Z)(Z)O-Linker-OP(Z)(Z)O-oligonucleotide, a nucleotide, an oligonucleotide, - P(Z)(Z)-formula(I), -P(Z)(Z)- or -Linker-R; R is L^(G), -Linker-L^(G), or has the structure shown below: L^(G) is independently for each occurence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R^(N) is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z, Z, Z and Z are each independently for each occurrence O or S.


Patent
Alnylam Pharmaceuticals | Date: 2016-03-16

The invention relates to sirens targeting a PCs gene, and methods of using sirens to inhibit expression of PCs and to treat PCs related disorders, e.g., hyperlipidemia.


Patent
Alnylam Pharmaceuticals | Date: 2016-09-09

The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agentto targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.


The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.


Patent
Alnylam Pharmaceuticals | Date: 2016-03-03

This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.

Loading Alnylam Pharmaceuticals collaborators
Loading Alnylam Pharmaceuticals collaborators